Clinical trial NCT03861780: Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation
Official title: Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bacteria Microflora Reduction
Lead sponsor: Professional Disposables International, Inc.
Sponsor class: INDUSTRY
First posted: 2019-03-04
Enrollment: 152
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Comparative Study of Antimicrobial Effectiveness Evaluation of 26ml Project X, 5.1ml Project X and Prevantics Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of Preoperative, Precatheterization, or Preinjection Skin Preparations, ASTM International, West Conshohocken, Pennsylvania, 2015


Eligibility criteria: Inclusion Criteria:

* Subjects may be of either sex, at least 18 years of age, and of any race.
* Subjects must be able to read and understand English.
* Subjects must have read and signed an Informed Consent Form, Authorization to Use and Disclose Protected Health Information Form, and List of Restricted Products prior to participating in the study, all located in the separate Informed Consent documents.
* Subjects must be in good general health and have no medical diagnosis of a physical condition, such as a current or recent severe illness, medicated or uncontrolled diabetes, hepatitis B, hepatitis C, an organ transplant, mitral valve prolapse with heart murmur, fibromyalgia, ulcerative colitis, Crohn's disease, an immunocompromised condition such as AIDS (or HIV positive), lupus, or medicated multiple sclerosis.
* Subjects will have test sites on the skin of the abdomen and/or inguinal free of injury and in good condition (no active skin rashes, excessive freckling, moles, scratches, breaks in the skin, etc.) and have no currently active skin diseases or skin conditions (for example, contact dermatitis, psoriasis or eczema) that may compromise subject safety or study integrity.
* Subjects must have skin within 6 inches of the test sites that is free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders. Subjects with tattoos, scars, active skin rashes, or breaks in the skin of test sites, skin blemishes, such as dry scabs or warts, may be admitted at the discretion of the Principal Investigator, Subinvestigators, or Consulting Physicians.

Exclusion Criteria:

* Known allergies to vinyl, latex (rubber), alcohols, metals, tapes or adhesives, inks, sunscreens, deodorants, laundry detergents, topically applied fragrances, cleansers, or to common antibacterial agents found in soaps or lotions, particularly chlorhexidine gluconate or ethanol.
* Have experienced hives (raised welts) as a reaction to anything that contacted the skin.
* Use of systemic or topical antibiotic medications during the 14-day pre-test period through completion of testing on the single test day.
* Use of systemic or topical steroids, other than for contraception, hormone therapy, post-menopausal indications, during the 14-day pre-test period through completion of testing on the single test day. This includes steroid medications used to treat asthma. Note: topically applied hormonal steroids used for post-menopausal reasons must not get on the test sites.
* Any type of port (or portacath) or Peripherally Inserted Central Catheter (PICC).
* Pregnancy, plans to become pregnant or impregnate a sexual partner within the pre-test and test period of the study, or nursing a child. Female subjects must have a negative urine pregnancy test documented before treatment with test materials.
* Current participation or participation in a clinical study in the past 14 days.
* Any medical condition or use of any medications that, in the opinion of the Principal Investigator or consulting physicians, would preclude participation.

Primary outcomes:
measure: Change in Bacterial Microflora on the Inguinal Area
timeFrame: 30 seconds
measure: Change in Bacterial Microflora on the Inguinal Area
timeFrame: 10 minutes
measure: Change in Bacterial Microflora on the Inguinal Area
timeFrame: 6 hours
measure: Change in Bacterial Microflora on the Abdomen Area
timeFrame: 30 seconds
measure: Change in Bacterial Microflora on the Abdomen Area
timeFrame: 10 minutes
measure: Change in Bacterial Microflora on the Abdomen Area
timeFrame: 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Bozeman
country: United States
facility: Bioscience Laboratories Inc
state: Montana
Study officials:
affiliation: BioScience Laboratories, Inc.
name: Collette Duley
role: PRINCIPAL_INVESTIGATOR
References: